Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in CNS disorder therapeutics, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. Sharon Mates, Ph.D., the company's CEO and Chairman, is scheduled to present on Tuesday, August 13, 2024, at 12:00 p.m. ET in Boston, MA.
Investors and interested parties can access the live and archived webcast of the presentation through the company's website at www.intracellulartherapies.com under the 'Events & Presentations' section in Investor Relations. Attendees are advised to log in 5-10 minutes early to register and install any necessary software for viewing the presentation.
Intra-Cellular Therapies (Nasdaq: ITCI), una compagnia biofarmaceutica specializzata in terapie per i disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Sharon Mates, Ph.D., CEO e Presidente dell'azienda, presenterà martedì 13 agosto 2024, alle 12:00 p.m. ET a Boston, MA.
Gli investitori e gli interessati possono accedere al webcast in diretta e registrato della presentazione attraverso il sito web dell'azienda su www.intracellulartherapies.com nella sezione 'Eventi e Presentazioni' delle Relazioni con gli Investitori. Si consiglia ai partecipanti di accedere 5-10 minuti prima per registrarsi e installare eventuale software necessario per visualizzare la presentazione.
Intra-Cellular Therapies (Nasdaq: ITCI), una empresa biofarmacéutica especializada en terapias para trastornos del sistema nervioso central, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. Sharon Mates, Ph.D., CEO y presidenta de la empresa, está programada para presentar el martes 13 de agosto de 2024, a las 12:00 p.m. ET en Boston, MA.
Los inversores y partes interesadas pueden acceder al webcast en vivo y grabado de la presentación a través del sitio web de la empresa en www.intracellulartherapies.com en la sección 'Eventos y Presentaciones' en Relaciones con Inversores. Se aconseja a los asistentes iniciar sesión de 5 a 10 minutos antes para registrarse e instalar cualquier software necesario para ver la presentación.
인트라셀룰러 테라피스 (Nasdaq: ITCI)는 CNS 장애 치료제를 전문으로 하는 생명공학 기업으로, 캐너콜드 제뉴이티 제44회 연례 성장 컨퍼런스에 참가한다고 발표했습니다. 샤론 메이츠, Ph.D., 회사의 CEO이자 회장이 2024년 8월 13일 화요일 오후 12시(동부 표준시)에 매사추세츠주 보스턴에서 발표할 예정입니다.
투자자와 관련자는 www.intracellulartherapies.com의 '투자자 관계' 섹션의 '이벤트 및 발표'에서 프레젠테이션의 실시간 및 녹화 웹캐스트에 접근할 수 있습니다. 참석자는 프레젠테이션을 보기 위해 5-10분 일찍 로그인하여 등록하고 필요한 소프트웨어를 설치할 것을 권장합니다.
Intra-Cellular Therapies (Nasdaq: ITCI), une société biopharmaceutique spécialisée dans les thérapeutiques pour les troubles du système nerveux central, a annoncé sa participation à la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity. Sharon Mates, Ph.D., CEO et présidente de l'entreprise, doit faire une présentation le mardi 13 août 2024, à 12h00 ET à Boston, MA.
Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct et enregistré de la présentation via le site web de l'entreprise à l'adresse www.intracellulartherapies.com dans la section 'Événements et Présentations' des Relations avec les Investisseurs. Il est conseillé aux participants de se connecter 5 à 10 minutes à l'avance pour s'enregistrer et installer le logiciel nécessaire pour visionner la présentation.
Intra-Cellular Therapies (Nasdaq: ITCI), ein biopharmazeutisches Unternehmen, das sich auf Therapeutika für Erkrankungen des zentralen Nervensystems spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstumskonferenz von Canaccord Genuity angekündigt. Sharon Mates, Ph.D., die CEO und Vorsitzende des Unternehmens, wird am Dienstag, den 13. August 2024, um 12:00 Uhr ET in Boston, MA, präsentieren.
Investoren und Interessierte können auf das Live- und Archiv-Webcast der Präsentation über die Unternehmenswebsite unter www.intracellulartherapies.com im Abschnitt 'Veranstaltungen & Präsentationen' im Bereich Investor Relations zugreifen. Es wird empfohlen, sich 5-10 Minuten vor Beginn einzuloggen, um sich zu registrieren und die erforderliche Software zur Ansicht der Präsentation zu installieren.
- None.
- None.
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
646-930-4406
FAQ
When is Intra-Cellular Therapies (ITCI) presenting at the Canaccord Genuity 44th Annual Growth Conference?
Who will be presenting for Intra-Cellular Therapies (ITCI) at the Canaccord Genuity conference?
How can investors access Intra-Cellular Therapies' (ITCI) presentation at the Canaccord Genuity conference?
What is the main focus of Intra-Cellular Therapies (ITCI) as a company?
